OCTREOTIDE (OCTREOTIDE ACETATE)

USDailyMed:Octreotide AU:C H01CB02(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-only (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenyl-propanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide 83150-76-9Y135467-16-2(pamoate)as acetate:79517-01-4 Octreotideas acetate:448601 2055 DB00104Yas acetate:DBSALT000130 395352Nas acetate:5293182 RWM8CCW8GPas acetate:75R0U2568I D00442Nas acetate:D06495 CHEBI:7726 ChEMBL1680Nas acetate:ChEMBL1200480 DTXSID004868‍​‍‍‍​‍‍‍‍‍‍‍‍​‍2 Interactive image C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)Cc2c[nH]c3c2cccc3)Cc4ccccc4)NC(=O)[C@@H](Cc5ccccc5)N)C(=O)N[C@H](CO)[C@@H](C)O)O InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1NKey:DEQANNDTNATYII-OULOTJBUSA-NN Octreotide, sold under the brand nameSandostatinamong others, is an octapeptidethat mimics naturalsomatostatinpharmacologically, though it is a more potent inhibitor ofgrowth hormone,glucagon, andinsulinthan the natural hormone. It was first synthesized in 1979 and binds predominantly to the somatostatin receptorsSSTR2andSSTR5. It was approved for use in the United States in 1988.Octreotide was approved for medical use in the European Union in 2022.As of June 2020[update], octreotide is the first oral somatostatin analog (SSA) approved by the FDA.It is on theWorld Health Organization's List of Essential Medicines.